US, Japanese to trial NZ lung cancer drug
August 5th, 2011
Japanese and American companies plan to commission clinical trials of a promising lung cancer drug developed in New Zealand.
The drug, called PR610, is part of a new class developed by scientists at the Auckland Cancer Society Research Centre and the Maurice Wilkins research centre. They preserve healthy tissue by becoming active only in the “hypoxic” parts of tumours – the zones without oxygen.